Q3 Ends With A Hard Close on Thursday — $AMC $ATOS $INMB $INVO $SHIP $SPCE Move Higher!
- Published Sep 30, 2021
- Apple
- Current Coverage
- Fate Therapeutics, Inc.
- InMed Pharmaceuticals Inc.
- INmune Bio Inc.
- INVO Bioscience
- Market News
Happy End Of The Quarter!
I hope that you all had a wonderful day in general, but unfortunately the markets were decidedly working against us from the start and closed even lower going in to the end of this last session of the quarter. The S&P 500 closed at 4,307.54 (-1.19%), the Dow 30 closed at 33,843.92 (-1.59%), & the Nasdaq closed at 14,448.48 (-.44%). 11 0f the 11 sectors closed in the red with the industrials sector leading the descent realizing a sizable 2.1% drop. The markets seemed to be taking to heart or using the widely reported fear of the of US debt ceiling issue or at least using it as excuse to cash in some profits made in the large caps this year as no other really significant news hit the tape today. Although, along those lines, the US Congress did mange to find it in their hearts to pass the continuing resolution bill to sufficiently fund the government through Dec. 3. The market selloff could also be partly attributed to a few managers locking in their numbers for the quarter as well.
It is worth noting that the macroeconomic schedule did serve a few somber reports, but nothing too alarming, including the Initial jobless claims report for the week ending September 25, which confirmed a rise by by 11k to 362k, while continuing claims for the week ending September 18 fell by 18k to 2.802M. The third estimate for Q2 GDP ticked up to 6.7 & the GDP Deflator remained at 6.1%. The Chicago PMI fell to 64.7 in September.
Oil prices rose again to close at $75.07/bbl rising .2%. The 10-yr yield curve moved lower today as the 10-yr treasury yield closed at 1.53% moving down 1 basis point, while the 2-yr yield remained at .29%. The U.S. Dollar Index moved down .1% to 94.25.
The small caps on the Russell 2000 fell another -.94% closing at 2,204.37. The MicroCaps also fell again as the iShares Micro-Cap ETF (IWC) closed at $144.32, (-.39%) but jumped to $155,+7.4% in the aftermarkets….
The precious metals markets ended with gold prices closing at $1,757, +$29 and silver closed at $22.17, +$.61.
Tomorrow’s macroeconomic schedule will bring forth the ISM Manufacturing Index report for September, the Personal Income and Spending report for August, the PCE Prices report for August, the final Univ. of Michigan Index of Consumer Sentiment report for September, the Construction Spending report for August, & the final Markit Manufacturing PMI report for September.
BIOTECH TURNS GREEN – $ATOS, $INM, $INMB MOVE FORWARD
The SPDR S&P Biotech ETF (XBI) closed at $125.71, +.06%, the iShares Nasdaq Biotechnology ETF (IBB) closed at $161.68, +.17% & the NYSE ARCA Biotech Index (^BTK) closed at 5,679.05, +.49%.
Atossa Therapeutics (ATOS) announced that it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
InMed Pharmaceuticals (INM) announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
TECH LOWER – $NFLX CONTINUES
A few tech giants closed as follows: Alphabet (GOOG) closed at 2,665.31, -.93%, Facebook (FB) closed at $339.39, -.06%, Amazon (AMZN) closed at $3,285.04, -.45%, Microsoft (MSFT) closed at $281.92, -.73%, Apple (AAPL, $141.50, -.93%), Netflix (NFLX, $610.34, +1.88%), Salesforce (CRM, $271.22, +.27%) & Tesla (TSLA, $775.48, -.75%).
DISNEY
Shares of The Walt Disney Company (DIS) closed at $169.17, -2.03%. On Friday, Disney World will turn the big “Five-O”.
MEMES WATCH
AMC Entertainment (AMC) closed at $38.06, +7.09%. AMC announced today that it has exercised an option to repurchase $35 million of its 15% cash / 17% payment-in-kind (“PIK”) Toggle First Lien Secured Notes due 2026. The total cost to exercise this repurchase option was $41.3 million, including principal and accrued and unpaid interest. As a result of this debt reduction, AMC’s annual interest cost has been reduced by $5.25 million.
GameStop (GME) closed at $175.47, -.26%. On Sept. 20, GameStop announced that the Company plans to hire up to 500 employees at its newly-leased customer service center in Pembroke Pines, Florida. The new facility is expected to be operational by the end of 2021.
Virgin Galactic Holdings (SPCE) closed at $25.30, +12.15%. After the markets closed yesterday Virgin Galactic, a vertically integrated aerospace and space travel company, announced that it is cleared to fly FAA-licensed spaceflights following the conclusion of an FAA inquiry that focused on air traffic control clearance and real-time mission notification related to the Unity 22 flight in July. Michael Colglazier, Chief Executive Officer of Virgin Galactic, said: “Our entire approach to spaceflight is guided by a fundamental commitment to safety at every level, including our spaceflight system and our test flight program. We appreciate the FAA’s thorough review of this inquiry. Our test flight program is specifically designed to continually improve our processes and procedures. The updates to our airspace and real-time mission notification protocols will strengthen our preparations as we move closer to the commercial launch of our spaceflight experience.”
Shares of infamous ‘meme brokerage’ firm Robinhood Markets, Inc., (HOOD) closed at $42.08, -2.43%, but still above the $38 IPO offering price.
Shares of Seanergy Maritime Holdings Corp. (SHIP) closed at $1.45, +2.11%.
VP WATCHLIST HIGHLIGHTS
Our complete VP Watchlist is a list that we believe deserves consideration for short term and long term portfolio adds that include Apple, Tesla, Disney & 8 other names currently. The dedicated pages for each of these companies will enable you to stay informed and learn more about these companies daily. Please review few of the updates on a few of the VP Watchlist companies below:
- Shares of VP Watchlist stock, INmune Bio (NASDAQ: INMB) closed trading at $19.40, +1.40% after reaching an intraday high of $20.23.
-
- I hosted a FREE Tribe Public Presentation and Q&A event with INMB management today, Thursday, September 30 at 8:30am PT/11:30am ET. INmune Bio’s (NASDAQ: INMB) CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss delivered their presentation titled “Improving White Matter Integrity In Alzheimer’s Disease” & and were available for a brief Q&A session. Please view the video now to learn more.
-
- On Wednesday, Sept. 1, INMB announced that XPro™ (pegipanermin), the Company’s selective DN-TNF inhibitor candidate for the treatment of Alzheimer’s disease (AD), treatment resistant depression, and other neurological diseases where neuroinflammation is implicated, has been found to decrease multiple species of Phospho Tau (pTau) and improve neuroimaging biomarkers of myelination in patients with AD. INmune Bio management will host an investor webinar to review these findings and additional phase 1b data in greater detail on September 7, 2021 at 4:30 pm ET The Registration Link is https://us06web.zoom.us/webinar/register/WN_IlMwrkPGRa63319QM91YFg. Learn more bout INmune Bio (INMB) by clicking here.
-
- After the market closed Thursday, Aug. 25th, INmune Bio announced that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted by previously published in vitro experiments. NK cells need multiple activating signals to progress from a resting state to the triggering of cytolysis and cytokine secretion. INmune Bio has studied these pathways extensively and demonstrated that binding of NK cells with INKmune™ provides multiple activating signals and drives resting NK to the phenotype of memory-like NK (mlNK) cells with enhanced cancer-killing function. The company believes that this is the first ever successful generation of mlNK cells in patients. INMB Shares have traded over $20 in the aftermarkets.
-
- On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
-
- On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE.
- Shares of Fate Therapeutics (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, closed at $59.27/share, -.89%. The 52-wk high is $121.16.
-
- On September 15, Fate Therapeutics announced the publication of preclinical data demonstrating that its off-the-shelf, multiplexed-engineered, iPSC-derived NK cell product candidate FT538 exhibits significantly enhanced serial killing and functional persistence compared to peripheral blood NK cells. The superior anti-tumor activity of FT538 was attributable to its novel engineered components, including the knockout of CD38 and the expression of IL-15/IL-15R fusion protein, which were shown to improve metabolic fitness, increase resistance to oxidative stress, and induce transcription of proteins that control NK cell activation and effector function. The data were published in Cell Stem Cell in an online article entitled “Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy”.
- INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Shares of INVO closed at $3.26, +2.84%.
-
- On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
-
On September 7th, INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY.
- On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”
-
- On Aug.2, INVO announced the Company’s first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, was officially opening on August 9, 2021. Dr. Hammond commented, “With the opening of the country’s first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.”
-
- On July 14th, INVO announced the appointment of world renowned women’s health expert, Dr. Barbara Levy, M.D., FACOG, FACS as the Company’s Senior VP, Global Clinical Integration to accelerate affordable infertility treatment INVOcell’s Global OB/GYN Clinical Integration Strategy. Dr. Levy is considered one of the most influential clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee. She joins INVO Bioscience to help further develop and accelerate the Company’s global OB/GYN channel strategy. Steve Shum, CEO of INVO Bioscience, said, “We are excited to have Dr. Levy join the INVO team to support our mission to bring care to the vast underserved patient population around the world experiencing infertility challenges. She has a clear understanding of the role that OB/GYNs can play in helping to democratize fertility care on a global basis by providing accessibility to affordable and effective treatments, the key hallmarks of the INVOcell technology. We look forward to leveraging her experience, relationships, and influence to accelerate our OB/GYN clinical implementation strategy in the years to come.”
-
- Over the past 40+ years, since the first IVF baby was born, the fertility market has grown into a $20+ billion global industry. Here in the U.S., according to the most recent 2019 CDC data, approximately 330,000 IVF cycles were performed across 448 clinics, which implies a roughly $5 billion domestic marketplace. However, this represents only a small portion of the actual market as approximately 90% of infertile couples go untreated each year. There are some real challenges with bridging the gap of treating the volume of patients that need care. Patient affordability and lack of insurance coverage is often the most discussed dynamic, but that is only one part of the challenge. We believe that there is an equal or even greater challenge related to capacity limitations in the industry given the relatively small number of IVF clinics and limited human resources available which are typically only available in major metropolitan areas. We believe that INVO Biosceince’s INVOcell, without the need of expensive lab build outs, can bring much needed capacity additions and access to the market beyond the major metropolitan areas at a more affordable price.
- Shares of VP Watchlist firm, Seattle-based Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $3.26, +3.49% on 6.26M shares of trading volume after reaching a high of $3.2970 in intraday trading.
-
- Today, September 30, Atossa announced it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease. “Even with vaccines becoming widely available, the COVID-19 pandemic continues to be an urgent global health crisis,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Enrolling the first two participants in this study marks a significant milestone in our goal of ultimately developing nebulized AT-H201 to improve lung function in patients with active disease, which may reduce the number of patients requiring ventilators, and in ‘long-haul’ patients who have residual pulmonary function damage. Up to one third of hospitalized patients have pulmonary function changes 60 days or more after recovering from COVID. The portability of nebulizers, already routinely used for other chronic lung disease, should allow for treatment at home.”
-
- On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
-
- On September 7th, Atossa adjourned its special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date. The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote. Atossa stockholders may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.
-
- On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
- Shares of VP Watchlist stock, InMed Pharmaceuticals, Inc. (NASDAQ: INM), a leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids, closed trading at $1.75. The 52-wk range is $1.62 – $8.94.
-
- Today, September 30, INmed announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease. This study will be taking place at eleven sites across seven countries including Austria, Germany, Greece, France, Italy, Israel and Serbia. Clinical Trial Applications (“CTAs”) have been filed in all participating countries with regulatory authority and ethics committee approvals currently in place in four countries (Austria, France, Greece, Israel). The first site initiation visit was completed at a clinical site in Austria, where screening for eligible patients will begin shortly. “The start of this Phase 2 clinical trial represents a very important step forward to test the efficacy of INM-755 (cannabinol) cream in treating epidermolysis bullosa, a disease that has very few treatment options,” stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed. “Based on our earlier studies, we are hopeful that our cannabinol cream will prove to be a safe and effective treatment for people living with this severe genetic skin disease.”
-
- I hosted the INM management team on the Tribe Public Network on Tuesday, September 21 for a 30-minute FREE Presentation and Q&A Webinar Event. Eric A. Adams, MIBS, CEO & President of InMed Pharmaceuticals (NASDAQ: INM) & Shane Johnson, MD, Co-Founder of BayMedica delievered a presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” They held a Q&A session at the end of the presentation. You may view the video of the event at the Tribe Public YouTube Channel here.
-
On September 13th, InMed announced that it has entered into a definitive agreement to acquire BayMedica Inc., a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks. Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches. InMed’s proprietary cannabinoid manufacturing process, IntegraSyn™, combined with BayMedica’s synthetic biology and chemical synthesis capabilities, will provide InMed with complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment. In parallel to cannabinoid manufacturing, the combined company will continue to explore the therapeutic potential of cannabinoids and novel cannabinoid analogs for pharmaceutical drug development, as well as expand commercial sales of rare cannabinoids to the consumer health and wellness sector. Revenues of BayMedica’s initial rare cannabinoid product, Prodiol® CBC (cannabichromene), have grown steadily since sales commenced in December 2019, with cumulative revenues in excess of US$2.5M. BayMedica leads the industry in large batch production of CBC with current batch sizes of more than 200kg and an ability to increase to metric ton quantities as market demand increases. BayMedica is focused on the wholesale to consumer health and wellness markets, including nutraceuticals, cosmetic, functional food and beverage, as well as animal health markets. In addition to CBC, BayMedica has several high value non-intoxicating rare cannabinoids in various stages of commercial manufacturing scale-up including CBDV, THCV, CBGV, CBT and CBN for the health and wellness markets.
- On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with a BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price target.
-
- On Aug.9th, I published an informative story titled “A Recent Discussion With The CEO of InMed Pharmaceuticals (NASDAQ: INM) Regarding Development Of IntegraSyn™, A Proprietary Manufacturing Approach To Economically Produce Pharmaceutical-Grade Cannabinoids” PLEASE READ NOW.
-
- On July 2nd, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.
Economic Reports
- On Tuesday, the Conference Board’s Consumer Confidence Index report confirmed a fall to 109.3 in September. The Advance report for International Trade in Goods for August confirmed a deficit of $87.6B, while the Advance report for Retail Inventories report for August showed a rise by .1%, & the Advance report for Wholesale Inventories report for August rose 1.2%. The July FHFA Housing Price Index report showed a rise by 1.4% M/M. The July S&P Case-Shiller Home Price Index report confirmed a 19.9% jump Y/Y.
- On Wednesday, the Pending home sales report confirmed a 8.1% M/M leap in August, while the weekly MBA Mortgage Applications Index report confirmed a drop by 1.1%. The weekly crude oil inventories rose by 4.58M barrels.
- On Thursday, the Initial jobless claims report for the week ending September 25, confirmed a rise by by 11k to 362k, while continuing claims for the week ending September 18 fell by 18k to 2.802M. The third estimate for Q2 GDP ticked up to 6.7 & the GDP Deflator remained at 6.1%. The Chicago PMI fell to 64.7 in September.
Investing & Inspiration
- “One fails forward toward success.” – Charles Kettering
- “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
- “I hear and I forget. I see and I remember. I do and I understand.” – Confucius
- “I’m a very strong believer in listening and learning from others.” – Ruth Bader Ginsburg
- “Blessed are those who give without remembering and take without forgetting.” – Elizabeth Bibesco
- “As you walk down the fairway of life you must smell the roses, for you only get to play one round.” – Ben Hogan
- “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
- “Economics is all about consumption. People either spend money now or they use financial instruments – like bonds, stocks and savings accounts – so they can spend more later.” – Adam Davidson
- “Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better.” -Samuel Beckett
- “In the post-industrial economy, ideas and great minds often provide far greater return on investment than any other resources or capital investments.” – Marvin Ammori
- “Work like you don’t need the money. Love like you’ve never been hurt. Dance like nobody’s watching.” – Satchel Paige
- “One of the rules I’ve learned is that struggling to try and think your way into making an investment is usually the best way to not have a great outcome.” – Stephen A. Schwarzman
- “The secret of business is to know something that nobody else knows.” – Aristotle Onassis
- “It takes a long time to grow an old friend.” – John Leonard
- “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.”– Sholom Aleichem
- “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
- “Man is only great when he acts from passion.” – Benjamin Disraeli
- “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
- “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
- “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
- “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
- “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
- “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
- “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein
- “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary
- “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
- “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
- “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
- “Every good painter paints what he is.” – Jackson Pollock
- “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
- “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
- “You cannot have a positive life and a negative mind.” – Joyce Meyer
- “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
- “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian
- “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings
- “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
- “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
- “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul
-
“Eliminate emotion from your investment program.” -John C. Bogle
- “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton
- “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
- “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
- “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
- “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
- “To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
- “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.” – Jesse Owens
- “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
- “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
- “The secret of your future is hidden in your daily routine.” – Mike Murdock
- “If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
- “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
- “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
-
“Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato
- “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda
- “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
-
“If you don’t know where you are going, any road will get you there.” – Lewis Carroll
-
“Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube
-
“It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
- “Prediction is very difficult, especially if it’s about the future.” – Niels Bohr (Danish Physicist)
-
“It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson
-
“The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks
- “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
- “Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
- “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
- “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
-
“View health as an investment, not an expense.” – John Quelch
-
“Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler
- “If you don’t know where you are going, any road will get you there.” – Lewis Carroll
- “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
- “That which does not kill us makes us stronger.” – Friedrich Nietzsche
- “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
- “A problem is a chance for you to do your best.”– Duke Ellington
- “The best way to predict the future is to create it.” -Peter Drucker
- “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
- “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
- “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
- “While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
- “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sack
- “We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” – Deb Haaland
- “The only way to have a friend is to be one.” – Ralph Waldo Emerson
- “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
-
“Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede
- “Success is not final, failure is not fatal: it is the courage to continue that counts.”– Winston Churchill
-
“Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius
- “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
- “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
- “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
- “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
- “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
- “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
-
“When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn
- “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
- “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
-
“Modern medical advances have helped millions of people live longer, healthier lives.
-
We owe these improvements to decades of investment in medical research.”– Ike Skelton
-
“Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson
- “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
- “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
- “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
- “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
- “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
- “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
- “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
- “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
- “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
- “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
- “No stock price is too low for bears or too high for bulls.” – John F. Heerdink, Jr.
-
“Investment is most successful when it is most businesslike.” – Ben Graham
-
“Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne
- “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
- “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
- “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
- “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
- “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
- “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― W
- “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
- “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
- “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
- “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
- “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
- “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
- “Know what you own, and know why you own it.” – Peter Lynch
- “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
- “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz
-
“Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis
- “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
-Jeremy Siegel - “With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
- “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
-
“The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
-
“Never depend on a single income, make an investment to create a second source.” Warren Buffet
- “Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
― Warren Buffett - “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
- “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
- “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
- “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
- “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
- “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
- “The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
- “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
- “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
- “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
- “No Price is too low for a bear or too high for a bull.” — Anonymous
- “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” Anonymous
- “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
- “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
- “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
- “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
- “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
- “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
- “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
- “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
- “Never count on making a good sale. Have the purchase price be so attractive that even a mediocre sale gives good results” — Warren Buffett
- “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
- “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
- “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
- “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr.
- “Know what you own, and know why you own it.” – Peter Lynch
- “Liquidity is only there when you don’t need it.” -Old Proverb
- “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
- “Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
- “In investing, what is comfortable is rarely profitable.” – Robert Arnott
- “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
- “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
- “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – Pope Francis
- “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
- “An investment in knowledge pays the best interest.” – Benjamin Franklin.
- “I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
- “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
- “The tax on capital gains directly affects investment decisions, the mobility, and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
- “If all the economists were laid end to end, they’d never reach a conclusion. -George Bernard Shaw
- “There are old traders and there are bold traders, but there are very few old, bold traders.”-Ed Seykota
- “Let this scenario play out on its own, in its own fashion. As you watch it unfold, you will soon be grateful that you choose the peaceful path. Remember — those who live by the sword, die by the sword.”
- “As long as you enjoy investing, you’ll be willing to do the homework and stay in the game.” -Jim Cramer
- “I rarely think the market is right. I believe non-dividend stocks aren’t much more than baseball cards. They are worth what you can convince someone to pay for it.” -Mark Cuban
- “Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
- “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
- “The only true test of whether a stock is “cheap” or “high” is not its current price in relation to some former price, no matter how accustomed we may have become to that former price, but whether the company’s fundamentals are significantly more or less favorable than the current financial-community appraisal of that stock.” -Philip Fisher
- “I learned to avoid trying to catch up or double up to recoup losses. I also learned that a certain amount of loss will affect your judgment, so you have to put some time between that loss and the next trade.” -Richard Dennis
- “The four most dangerous words in investing are: ‘this time it’s different.” -Sir John Templeton
- “Money doesn’t make you happy. I now have $50 million but I was just as happy when I had $48 million.” -Arnold Schwarzenegger
Videos
Please consider viewing these interesting videos:
Post View Count : 501